# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She wants to stay off heroin and keep singing, and is afraid of losing her tolerance and overdosing **S**
- She wants to drink less, especially around shows **S**
- She wants her records kept private and to be treated without judgment **S**

## Your goals

- Stay on buprenorphine without interruption through six months, including through any return to use. Target: 1948-10-19. Recorded outcome: Taking buprenorphine 16 mg daily at six months; a three-day gap during a tour was followed by a brief return to use and an immediate restart, with no overdose. **S**
- Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit. Target: 1948-04-27. Recorded outcome: Two naloxone two-packs dispensed; her friend trained. **S**
- Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months. Target: 1948-10-19. Recorded outcome: PEth 22 ng/mL from 312; occasional light drinking, which she chose. **S**
- Hepatitis A and B vaccine series completed by six months. Target: 1948-10-19. Recorded outcome: Hepatitis B doses at intake and five weeks; hepatitis A doses at intake and six months. **S**
- PHQ-9 score below 5 by six months. Target: 1948-10-19. Recorded outcome: PHQ-9 4. **S**

## What we agreed to do

- Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test strips. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Addiction medicine consultation to confirm the medication plan, choose a medicine for alcohol use disorder that can be used with buprenorphine, and set the monitoring plan. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Alcohol care: acamprosate, thiamine, brief counseling and goals she chooses, and PEth at each check to follow drinking without relying on memory. Guideline: Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immune. Guideline: Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020); Human Immunodeficiency Virus (HIV) Infection: Screening (2019) **S**
- Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Integrated, trauma-informed recovery plan: weekly counseling, a peer recovery coach, confidentiality she controls, and a written plan for touring, without requiring recovery to be perfect or linear. Guideline: Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**

## Follow-up

- 1948-04-20: Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening **S**
- 1948-04-27: One-week buprenorphine check and addiction medicine consultation **S**
- 1948-05-26: Five-week recovery review and second hepatitis B vaccine **S**
- 1948-07-20: Three-month review after a return to opioid use: adjusting the recovery plan **S**
- 1948-08-31: Periodic adult preventive visit **S**
- 1948-10-19: Six-month recovery, alcohol, liver, and mood review **S**

This teaching document does not replace care from a qualified clinician.
